Ugrás a tartalomra
Merck
Összes fotó(1)

Fontos dokumentumok

198M-1

Sigma-Aldrich

CD123 (6H6) Mouse Monoclonal Antibody

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez


About This Item

UNSPSC kód:
12352203
NACRES:
NA.41
klón:
6H6, monoclonal
application:
IHC (p)
faj reaktivitás:
human
technika/technikák:
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
citations:
4

biológiai forrás

mouse

Minőségi szint

100
500

konjugátum

unconjugated

antitest forma

culture supernatant

antitest terméktípus

primary antibodies

klón

6H6, monoclonal

leírás

For In Vitro Diagnostic Use in Select Regions (See Chart)

Forma

buffered aqueous solution

faj reaktivitás

human

kiszerelés

vial of 0.1 mL concentrate (198M-14)
vial of 0.5 mL concentrate (198M-15)
bottle of 1.0 mL predilute (198M-17)
vial of 1.0 mL concentrate (198M-16)
bottle of 7.0 mL predilute (198M-18)

gyártó/kereskedő neve

Cell Marque

technika/technikák

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

izotípus

IgG1κ

szabályozó

blastic plasmacytoid dendritic cell neoplasm

kiszállítva

wet ice

tárolási hőmérséklet

2-8°C

vizualizáció

cytoplasmic

Általános leírás

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as CD4+/CD56+ hematodermic neoplasm or blastic NK-cell lymphoma, is a malignant neoplasm composed of immature hematopoietic precursors of plasmacytoid dendritic cells. The most frequent manifestation is a skin lesion, bone marrow involvement, and regional lymphadenopathy. Myeloid leukemia cutis (LC), myeloid sarcoma, and large aggressive B cell lymphomas should be differentiated from BPDCN. Recently, it has been reported that these entities can be distinguished by using immunohistochemistry (IHC) in paraffin-embedded tissue sections. In this study, 23 myeloid LC and 12 BPDCN cases were evaluated using a panel of antibodies against CD123, TCL1, CD4, CD56, MPO and CD33; with results as follows: anti-CD123 stained 4 cases (17%) of myeloid LC and 10 cases (83%) of BPDCN; anti-TCL-1 stained 2 cases (9%) of myeloid LC and 9 (82%) of 11 cases of BPDCN; anti-CD4 stained 2 cases (9%) of LC and all 12 cases (100%) of BPDCN; anti-CD56 stained 12 cases (52%) of LC and all 12 cases (100%) of BPDCN; anti-myeloperoxidase stained 7 cases (30%) of LC and 0 cases (0%) of BPDCN. Anti-CD33 was not helpful; it stained 18 (78%) cases of LC and 11 cases (92%) of BPDCN. The results indicated that a panel that includes antibodies against CD4, CD56, CD123, and TCL-1 can appropriately distinguish between myeloid LC and BPDCN.
CD123 IHC expression has been studied in 157 acute myeloid leukemia (AML) bone marrow biopsies and/or marrow particle preparations, and correlated with the morphologic, immunophenotypic, and cytogenetic features and with the presence of FLT3-ITD and NPM1 mutations. CD123 IHC expression has been seen in 40% of AML, across a wide spectrum of 2008 World Health Organization subtypes and was most frequent within the intermediate risk group. Compared with CD123 IHC negative AML, CD123 IHC positive AML demonstrated higher marrow blast percentages (median 69%), monocytic differentiation (33/63 cases), and CD34 negativity (29/63 cases). 83% (25/30) FLT3-ITD-mutated AML were CD123+ and 62% (18/29) NPM1-mutated cases were CD123 IHC+ (P=0.0052). CD123 IHC+AML presents with characteristic pathologic features, some of which may be related to underlying FLT3-ITD and/or NPM1 mutations.

Minőség


IVD

IVD

IVD

RUO

Kapcsolódás

CD123 Positive Control Slides, Product No. 198S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Fizikai forma

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Elkészítési megjegyzés

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Egyéb megjegyzések

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Jogi információk

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Nem találja a megfelelő terméket?  

Próbálja ki a Termékválasztó eszköz. eszközt

Tárolási osztály kódja

12 - Non Combustible Liquids

WGK

WGK 2

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable


Válasszon a legfrissebb verziók közül:

Analitikai tanúsítványok (COA)

Lot/Batch Number

Nem találja a megfelelő verziót?

Ha egy adott verzióra van szüksége, a tétel- vagy cikkszám alapján rákereshet egy adott tanúsítványra.

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Marian Rollins-Raval et al.
Applied immunohistochemistry & molecular morphology : AIMM, 21(3), 212-217 (2012-08-24)
FLT3-ITD and NPM1 mutation testing in acute myeloid leukemia (AML) plays an important role in prognostic risk stratification, especially within the intermediate cytogenetic risk group. Molecular studies require adequate fresh material and are typically performed on a dedicated aspirate specimen
Facchetti F, et al.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 145-147 (2008)
Danielle M P Cronin et al.
American journal of clinical pathology, 137(3), 367-376 (2012-02-18)
Myeloid leukemia cutis (LC) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) are morphologically indistinguishable malignancies that frequently manifest in the skin. Separating myeloperoxidase-negative LC from BPDCN may be particularly challenging. We identified a panel of immunohistochemical stains to distinguish myeloid
Facchetti F, et al.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 145-147 (2008)

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással